Literature DB >> 28891079

Successful TS-1 monotherapy as the second-line treatment for advanced extramammary Paget's disease: A report of two cases.

Junji Kato1, Tokimasa Hida1, Toshiharu Yamashita1, Shiori Kamiya1, Kohei Horimoto1, Sayuri Sato1, Hitomi Takahashi1, Masahide Sawada1, Mao Yamada1, Hisashi Uhara1.   

Abstract

There is no standard chemotherapeutic treatment for advanced extramammary Paget's disease, though the effectiveness of some chemotherapy regimens, including docetaxel, has been reported. In this report, we report that TS-1 monotherapy was effective in two patients with advanced extramammary Paget's disease after docetaxel treatment failure. TS-1 monotherapy may be useful as the second-line treatment for patients with advanced extramammary Paget's disease.
© 2017 Japanese Dermatological Association.

Entities:  

Keywords:  TS-1 monotherapy; chemotherapy; docetaxel; extramammary Paget's disease; second line

Mesh：

Substances：

Year:  2017        PMID： 28891079     DOI： 10.1111/1346-8138.14017

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


  5 in total

Review 1.  [Extramammary Paget's disease].

Authors:  I Cosgarea; A Zaremba; U Hillen
Journal:  Hautarzt       Date:  2019-09       Impact factor: 0.751

Review 2.  Current Management and Treatment of Extramammary Paget's Disease.

Authors:  Hiroki Hashimoto; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-04-04

Review 3.  Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach.

Authors:  Keitaro Fukuda; Takeru Funakoshi
Journal:  Front Oncol       Date:  2018-02-16       Impact factor: 6.244

4.  NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target.

Authors:  Maho Murata; Takamichi Ito; Yuka Tanaka; Yumiko Kaku-Ito; Masutaka Furue
Journal:  Int J Mol Sci       Date:  2020-08-16       Impact factor: 5.923

5.  Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).

Authors:  Maki Ishii; Ikuko Hirai; Keiji Tanese; Takayuki Fusumae; Yoshio Nakamura; Keitaro Fukuda; Hiroshi Uchi; Kenji Kabashima; Atsushi Otsuka; Kenji Yokota; Naoya Yamazaki; Kenjiro Namikawa; Taku Fujimura; Tatsuya Takenouchi; Yuki Yamamoto; Mana Nishiguchi; Yasunori Sato; Masayuki Amagai; Takeru Funakoshi
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.